Clinuvel Pharmaceuticals Ltd has released a press release.
SCENESSE dosage expansion under review by EMA
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL prioritises three strategic programs
- Managing Director Presentation
- Canadian New Drug Submission for SCENESSE in EPP filed
- CLINUVEL delivers increases in annual revenue, profit
- Appendix 4E and Annual Report to Shareholders 2024
Later from Clinuvel Pharmaceuticals
- Chair's letter to Shareholders
- Health Canada validates SCENESSE New Drug Submission
- Vitiligo - CUV105 Study Update
- Preliminary results from SCENESSE adolescent EPP study
- Half Year Results Announcement
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals